Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor treatment options, emphasizing the need for novel therapeutic targets. Hub proteins have high connectivity (i.e., many interaction partners) and often act as central biological regulators. Here, we aimed to identify hub proteins with potential...
Foram Vyas, Virginie Defamie, Kelvin Yeung et al.· Cancer Research· 0 citations
Malignant cells do not exist in isolation. In pancreatic ductal adenocarcinoma (PDAC), malignant cells reside within distinct spatial niches shaped by stromal, immune, endothelial, and neural compartments, and this spatial context is linked to therapeutic resistance and clinical outcome. While genomic alterations dri...
Sibyl Drissler, Noor Shakfa, Elizabeth Sunnucks et al.· Cancer Research· 0 citations
The findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification.
Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al.· Cancer Research· 0 citations
Cellular heterogeneity in pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for disease prognosis and limits the effectiveness of therapeutic strategies implemented in recent multicenter subtype-based clinical trials worldwide. A hallmark of PDAC is extensive intratumoral heterogeneity, which is la...
Xue-Yan Wu, L. Klein, M. Tu et al.· Cancer Research· 0 citations
It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.
M. Dorsch, Felix E. G. Beaudry, A. Baginska et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.